The Circadian Clock in Cancer Development and Therapy - Progress in Molecular Biology and Translational Science - page 281

454. Kalra SP, Kalra PS. Neuroendocrine control of energy homeostasis: update on new
insights. Prog Brain Res . 2010;181:17-33.
455. Beaudry JL, Riddell MC. Effects of glucocorticoids and exercise on pancreatic beta-cell
function and diabetes development. Diabetes Metab Res Rev . 2012;28(7):560-573.
456. Roberge C, Carpentier AC, Langlois MF, et al. Adrenocortical dysregulation as a major
player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab . 2007;293
(6):E1465-E1478.
457. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secre-
tion. Diabetes Obes Metab . 2011;13(Suppl 1):82-88.
458. Chandra R, Liddle RA. Recent advances in pancreatic endocrine and exocrine secre-
tion. Curr Opin Gastroenterol . 2011;27(5):439-443.
459. Gale SM, Castracane VD, Mantzoros CS. Energy homeostasis, obesity and eating dis-
orders: recent advances in endocrinology. J Nutr . 2004;134(2):295-298.
460. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy bal-
ance. J Clin Invest . 2011;121(6):2087-2093.
461. Vansaun MN. Molecular pathways: adiponectin and Leptin signaling in cancer. Clin
Cancer Res . 2013;19:1926-1932.
462. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing
concern and an inflammatory (and microenvironmental) issue. Ann N Y Acad Sci .
Oct 2012;1271:82-87.
463. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway.
Cancer Cell . 2007;12(2):104-107.
464. Boudny V, Kovarik J. JAK/STAT signaling pathways and cancer. Janus kinases/signal
transducers and activators of transcription. Neoplasma . 2002;49(6):349-355.
465. Bodart JF. Extracellular-regulated kinase-mitogen-activated protein kinase cascade:
unsolved issues. J Cell Biochem . 2010;109(5):850-857.
466. Okwan-Duodu D, Umpierrez GE, Brawley OW, Diaz R. Obesity-driven inflamma-
tion and cancer risk: role of myeloid derived suppressor cells and alternately activated
macrophages. Am J Cancer Res . 2013;3(1):21-33.
467. Smorlesi A, Frontini A, Giordano A, Cinti S. The adipose organ: white-brown adipo-
cyte plasticity and metabolic inflammation. Obes Rev . Dec 2012;13(Suppl 2):83-96.
468. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature .
2006;441(7092):431-436.
469. Coussens LM, Werb Z. Inflammation and cancer. Nature . 2002;420(6917):860-867.
470. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated mac-
rophages in neoplastic progression and immune surveillance. Immunol Rev .

2008;222:155-161.
471. Koki A, Khan NK, Woerner BM, et al. Cyclooxygenase-2 in human pathological dis-
ease. Adv Exp Med Biol . 2002;507:177-184.
472. Khan Z, Pillay V, Choonara YE, du Toit LC. Drug delivery technologies for
chronotherapeutic applications. Pharm Dev Technol . 2009;14(6):602-612.
473. Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of
antibodies. J Hematol Oncol . 2012;5:70.
474. Lodish MB. Kinase inhibitors: adverse effects related to the endocrine system. J Clin

Endocrinol Metab . 2013;98:1333-1342.
475. Philip AK, Philip B. Chronopharmaceuticals: hype or future of pharmaceutics. Curr
Pharm Des . 2011;17(15):1512-1516.
476. Smaaland R. Circadian rhythm of cell division. Prog Cell Cycle Res . 1996;2:241-266.
477. Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer
treatments. Annu Rev Pharmacol Toxicol . 2010;50:377-421.
478. Levi F, Focan C, Karaboue A, et al. Implications of circadian clocks for the rhythmic
delivery of cancer therapeutics. Adv Drug Deliv Rev . 2007;59(9-10):1015-1035.